Accord BioPharma has tapped Eversana to support Camcevi, a treatment for advanced prostate cancer, in the U.S. The drug was approved by the Food and Drug Administration in May 2021 and is billed as the first sterile formulation of leuprolide for subcutaneous injection.

Eversana will provide Accord with a range of support services, including sales force deployment and training and channel management. Accord will also be able to avail itself of Eversana’s data and analytics platform.

Eversana president of field deployment solutions Krista Pinto said a key goal of the partnership is to connect with and spur awareness among healthcare providers across the country.